Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma

Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma

BackgroundLung adenocarcinoma (LUAD) is the most common pathological type of lung cancer, with high incidence and mortality. To improve the curative effect and prolong the survival of patients, it is necessary to find new biomarkers to accurately predict the prognosis of patients and explore new str...

Full description

Bibliographic Details
Main Authors: Yang Cheng, Kezuo Hou, Yizhe Wang, Yang Chen, Xueying Zheng, Jianfei Qi, Bowen Yang, Shiying Tang, Xu Han, Dongyao Shi, Ximing Wang, Yunpeng Liu, Xuejun Hu, Xiaofang Che
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
lung adenocarcinoma
prognosis
signature
drug repositioning
gliclazide
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.665276/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.665276/full

Similar Items